Evidence map›Paper›PMID 39799997›Full record

ArticleInternational journal of pharmaceutics2025

Genipin-crosslinked double PLL membranes overcome the strength-diffusion trade-off in cell encapsulation without compromising biocompatibility.

Edorta Santos-Vizcaino, María Virumbrales-Muñoz, Ainhoa Gonzalez-Pujana, Gary D Luker, Ignacio Ochoa, Rosa Maria Hernandez, Jose Luis Pedraz

Abstract read
In one paragraph

Article in International journal of pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Edorta Santos-VizcainoNanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV-EHU), 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain; Bioaraba, NanoBioCel Research Group, 01006 Vitoria-Gasteiz, Spain.
María Virumbrales-MuñozDepartment of Obstetrics and Gynecology, Clinical Sciences Center, 600 Highland Drive, Madison 53792, USA; School of Medicine and Public Health, University of Wisconsin-Madison, 1111 Highland Avenue, Madison 53705, USA; University of Wisconsin Carbone Cancer Center, 1111 Highland Avenue, Madison 53705, USA.
Ainhoa Gonzalez-PujanaNanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV-EHU), 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain; Bioaraba, NanoBioCel Research Group, 01006 Vitoria-Gasteiz, Spain.
Gary D LukerDepartment of Radiology (Center for Molecular Imaging), University of Michigan, Ann Arbor, MI, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.
Ignacio OchoaBiomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain; Tissue Microenvironment Lab (TME Lab), I3A, University of Zaragoza, 50018 Zaragoza, Spain; Aragón Health Research Institute (IISAragón), 50009 Zaragoza, Spain; School of Medicine, University of Zaragoza, 50009 Zaragoza, Spain.
Rosa Maria HernandezNanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV-EHU), 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain; Bioaraba, NanoBioCel Research Group, 01006 Vitoria-Gasteiz, Spain. Electronic address: rosa.hernandez@ehu.eus.
Jose Luis PedrazNanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV-EHU), 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain; Bioaraba, NanoBioCel Research Group, 01006 Vitoria-Gasteiz, Spain. Electronic address: joseluis.pedraz@ehu.eus.

Funding

University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
NCATS NIH HHS UL1 TR002373
6 · The paper itself

Abstract

Cell microencapsulation technologies allow non-autologous implantation of therapeutic cells for sustained drug delivery purposes. The perm-selective membrane of these systems provides resistance to rupture, stablishes the upper molecular weight limit in bidirectional diffusion of molecules, and affects biocompatibility. Thus, despite being a decisive factor to succeed in terms of biosafety and therapeutic efficacy, little progress has been made in its optimization so far. Here we show that, compared to other usually used coating designs, genipin-crosslinked double poly-L-lysine (GDP) membranes are able to simultaneously improve mechanical and mass-transport properties of the microcapsules, without causing any significant increase in the foreign body response when implanted in vivo. In particular, we show that GDP membranes confer capsular integrity under high pressures, both internal and external. Furthermore, this membrane design allows for more efficient bidirectional diffusion of molecules in the 20-40 kDa range while preserving the molecular weight cut-off required for exerting an effective immunobarrier. These findings may also be useful for optimizing the membrane characteristics of multiple drug delivery systems.

Indexed as

Cell EncapsulationIridoidsMembranes, ArtificialPolylysineAnimalsBiocompatible MaterialsCapsulesCross-Linking ReagentsDiffusionDrug Delivery SystemsHumansMiceBiocompatible MaterialsCapsulesCross-Linking ReagentsgenipinIridoidsMembranes, ArtificialPolylysineCell encapsulationForeign body reactionGenipinMechanical propertiesMembranesPermeability

Identifiers

PMID39799997
PMCPMC13200529

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.